Advertisement

Systematic Review Results on BCG Refractory Disease Management

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala
Chapter

Abstract

A systematic review relating to management in BCG refractory disease was conducted. The search strategy aimed to identify all references related to bladder cancer AND BCG refractory disease. This chapter covers systematic review results.

References

  1. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized phase III trial on gemcitabine versus mytomicin in recurrent NMI bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543–8.Google Scholar
  2. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int. 2009a;104(8):1098–102.CrossRefGoogle Scholar
  3. Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009b;27(3):331–5.CrossRefGoogle Scholar
  4. Bassi PF, Volpe A, D’Agostino D, Palermo G, Renier D, Franchini S, Rosato A, Racioppi M. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol. 2011;185(2):445–9.CrossRefGoogle Scholar
  5. Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, Crucitta E, Marini L, Dal Moro F. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urol Int. 2005;75(4):309–13.CrossRefGoogle Scholar
  6. Belldegrun AS, Franklin JR, O’Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD. NMI bladder cancer: the role of interferon-alpha. J Urol. 1998;159(6):1793–801.Google Scholar
  7. Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010;28(5):510–4.CrossRefGoogle Scholar
  8. Dalbagni G, Benfante N, Sjoberg DD, Bochner BH, Machele Donat S, Herr HW, Mc Coy AS, Fahrner AJ, Retinger C, Rosenberg JE, Bajorin DF. Single arm phase I/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus Calmette Guerin (NCT01259063). Bladder Cancer. 2017;3(2):113–119.CrossRefGoogle Scholar
  9. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–34.CrossRefGoogle Scholar
  10. Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, Viggiani F, Ghezzi P, Nesi G, Carini M; TUR (Toscana Urologia) Group. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006;76(2):106–11.CrossRefGoogle Scholar
  11. Gallagher BL, Joudi FN, Maymí JL, O’Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology. 2008;71(2):297–301.CrossRefGoogle Scholar
  12. Gunelli R, Bercovich E, Nanni O, Ballardini M, Frassineti GL, Giovannini N, Fiori M, Pasquini E, Ulivi P, Pappagallo GL, Silvestrini R, Zoli W. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer. 2007;97(11):1499–504.CrossRefGoogle Scholar
  13. Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009;27(5):496–501.CrossRefGoogle Scholar
  14. Karakiewicz PI, Benayoun S, Lewinshtein DJ, Chun FK, Shahrour K, Perrotte P. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience. Can J Urol. 2006;13(4):3189–94.Google Scholar
  15. Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald GC. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther. 2010;4:313–20.Google Scholar
  16. Luciani LG, Neulander E, Murphy WM, Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory NMI bladder cancer: an investigational approach. Urology. 2001;58(3):376–9.CrossRefGoogle Scholar
  17. McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186(2):448–51.CrossRefGoogle Scholar
  18. Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesicle gemcitabine in management of BCG refractory NMI TCC of urinary bladder-our experience. Urol Oncol. 2008;26(6):616–9.Google Scholar
  19. Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol. 2015;193(4):1135–43.CrossRefGoogle Scholar
  20. O’Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with NMI bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166(4):1300–4, discussion 1304–5.Google Scholar
  21. Patel S, Dinh T, Noah-Vanhoucke J, Rengarajan B, Mayo K, Clark PE, Kamat AM, Lee CT, Sexton WJ, Steinberg GD. Novel simulation model of non-muscle invasive bladder cancer: a platform for a virtual randomized trial of conservative therapy vs. Cystectomy in BCG refractory patients. Bladder Cancer. 2015;1(2):143–150.CrossRefGoogle Scholar
  22. Perdonà S, Di Lorenzo G, Cantiello F, Damiano R, De Sio M, Masala D, Bruni G, Gallo L, Federico P, Quattrone C, Pizzuti M, Autorino R. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21(1):101–6.CrossRefGoogle Scholar
  23. Rao MV, Quek ML, Jayram G, Ellimoottil C, Sondej T, Hugen CM, Flanigan RC, Steinberg GD. Radical cystectomy after bcg immunotherapy for high-risk nonmuscle-invasive bladder cancer in patients with previous prostate radiotherapy. ISRN Urol. 2013;2013:405064.CrossRefGoogle Scholar
  24. Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, DeCastro GJ, McKiernan JM. Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus calmette-guérin therapy. Urology. 2017;103:149–153.CrossRefGoogle Scholar
  25. Rosevear HM, Lightfoot AJ, Birusingh KK, Maymí JL, Nepple KG, O’Donnell MA; National BCG/Interferon Investigator Group. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. J Urol. 2011;186(3):817–23.Google Scholar
  26. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. 2017;35(30):3410–3416.CrossRefGoogle Scholar
  27. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–7.CrossRefGoogle Scholar
  28. Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. Postgrad Med. 2011;123(3):28–34.CrossRefGoogle Scholar
  29. Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. J Urol. 2013;190(5):1686–91.CrossRefGoogle Scholar
  30. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory NMI bladder cancer. J Urol. 2001;165(6 Pt 1):1904–7.Google Scholar
  31. Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol. 2011;186(5):2094–100.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations